Status:
COMPLETED
Budesonide / Formoterol in Treatment of Exacerbations of COPD
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the budesonide+formoterol combination is effective in the treatment of exacerbations of COPD with a main emphasis on investigating the effects on infl...
Eligibility Criteria
Inclusion
- smoking-induced COPD according to ATS criteria
- FEV1 \<85% of predicted at enrolment and \<70% of predicted but \> 0.7 Liter at Exacerbation
- FEV1/IVC ratio \<88% of predicted for men and \<89% for women
Exclusion
- history of asthma
- known hypersensitivity to the study drugs
- serious concomitant diseases
- pregnancy or lactating
- abnormal Chest X-ray or blood gasses
Key Trial Info
Start Date :
January 1 2001
Trial Type :
INTERVENTIONAL
End Date :
January 1 2005
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00239278
Start Date
January 1 2001
End Date
January 1 2005
Last Update
January 24 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Groningen, Netherlands